

Financial Tear Sheet

Corporate Profile

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid's drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in people with Angelman syndrome and completed a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.

Stock Performance

OVID (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	\$10.73
Change (%)	▲ 0.15 (1.42%)
Volume	33,343
52 Week High	\$12.44
52 Week Low	\$5.28
Market Cap	\$264,209,801
Rolling EPS	-1.54
PE Ratio	0
Shares Outstanding	24,623,467

Data as of July 20, 2018 4:00 p.m. ET



Recent Headlines

July 18, 2018

Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with Three New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)

July 11, 2018

Ovid Therapeutics Announces Presentations Related to OV101 Fragile X Syndrome Program at the 16th National Fragile X Foundation (NFXF) International Conference

July 11, 2018

Ovid Therapeutics Announces Initiation of Phase 2 ROCKET Clinical Trial to Evaluate OV101 in Fragile X Syndrome

SEC Filings

Filing Date	Form
-------------	------

July 19, 2018	8-K
---------------	-----

July 16, 2018	8-K
---------------	-----

June 19, 2018	EFFECT
---------------	--------

June 11, 2018	8-K
---------------	-----

Upcoming Events

There are currently no events scheduled.

Corporate Governance

Jeremy Levin, D.Phil.,
MB BChir

Chairman of the
Board of
Directors

Data provided by Nasdaq. Minimum 15 minutes delayed.

© Ovid Therapeutics.. All rights reserved.